Search results

  • ...f some drugs as [[substrate (chemistry)|substrates]] or [[enzyme inhibitor|inhibitors]] of enzymes involved in xenobiotic metabolism are a common reason for haza ...rihemoprotein oxidoreductase, NADPH:hemoprotein oxidoreductase, NADPH:P450 oxidoreductase, P450 reductase, POR, CPR, CYPOR, is a membrane-bound enzyme required for e ...
    29 KB (3,729 words) - 12:12, 15 November 2023
  • ...t increase activity. Many therapeutic [[drug]]s and [[poison]]s are enzyme inhibitors. An enzyme's activity decreases markedly outside its optimal [[temperature] *EC 1, [[Oxidoreductase]]s: catalyze [[oxidation]]/reduction reactions ...
    52 KB (7,533 words) - 19:19, 21 February 2024
  • ...t increase activity. Many therapeutic [[drug]]s and [[poison]]s are enzyme inhibitors. An enzyme's activity decreases markedly outside its optimal [[temperature] *EC 1, [[Oxidoreductase]]s: catalyze [[oxidation]]/reduction reactions ...
    54 KB (7,773 words) - 19:18, 21 February 2024
  • *EC 1の[[Oxidoreductase/ja|酸化還元酵素]]:[[oxidation/ja|酸化]]/還元反応を触媒する。 ...a|スタチン]]や、[[HIV/ja|HIV]]のような[[retroviral/ja|レトロウイルス]]感染の治療に用いられる[[protease inhibitors/ja|プロテアーゼ阻害剤]]がある。薬物として使用される不可逆的阻害剤の一般的な例は[[aspirin/ja|アスピリン]]であり、これは[[infl ...
    64 KB (2,204 words) - 15:33, 22 February 2024
  • ...al electron acceptor of the reaction catalyzed by the succinate:ubiquinone oxidoreductase complex, also acting as an intermediate in the [[electron transport chain]] ...yl 4-hydroxylases]]. Fumarate and succinate have been identified as potent inhibitors of prolyl hydroxylases, thus leading to the stabilisation of HIF. ...
    38 KB (5,368 words) - 11:38, 31 March 2024
  • ...al electron acceptor of the reaction catalyzed by the succinate:ubiquinone oxidoreductase complex, also acting as an intermediate in the [[electron transport chain]] ...yl 4-hydroxylases]]. Fumarate and succinate have been identified as potent inhibitors of prolyl hydroxylases, thus leading to the stabilisation of HIF. ...
    39 KB (5,478 words) - 11:38, 31 March 2024
  • ..., a "reverse type I" spectrum, by processes that are as yet unclear. Inhibitors and certain substrates that bind directly to the heme iron give rise to the * [[Cytochrome P450 oxidoreductase deficiency]] ...
    38 KB (5,401 words) - 20:37, 15 March 2024
  • ..., a "reverse type I" spectrum, by processes that are as yet unclear. Inhibitors and certain substrates that bind directly to the heme iron give rise to the * [[Cytochrome P450 oxidoreductase deficiency]] ...
    39 KB (5,513 words) - 20:35, 15 March 2024